RAS and coagulation in COVID-19 (a)
Research type
Research Study
Full title
Investigating the relationship between the renin angiotensin system and the coagulopathy associated with COVID-19
IRAS ID
284196
Contact name
David Owen
Contact email
Sponsor organisation
Imperial College London
Eudract number
n/a
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
n/a, n/a
Duration of Study in the UK
0 years, 6 months, 0 days
Research summary
WHY?
COVID-19 causes activation of a system called the RAS system (renin angiotensin system), and it also causes blood clotting. The blood clotting is thought to be a very important part of why some people with COVID-19 become seriously ill. When the RAS system is overactive, it can cause clotting. We would therefore like to find out whether the clotting that occurs in COVID-19 is to do with overactivation of the RAS system. If so, it may mean that blocking the RAS system could be a useful treatment for people who become ill with COVID-19WHAT?
There are lots of commonly used drugs which block part of the RAS system (for example “ace inhibitors”). However, the RAS system is complicated. Some components of the RAS system induce clotting and other components protect against it. Drugs like ace inhibitors block both of these components. We will therefore use a drug called TRV027, which specifically blocks the part of the RAS system which contributes clotting, but does not block the part which protects against clotting.WHO?
All patients with COVID-19 who are admitted to hospital, aged 65 or over, who are not in ITU will be invited to participateWHERE?
NHS Hospitals. Imperial College Healthcare NHS Trust is the main site.HOW?
Each participant will be randomised to receive either an infusion of TRV027 or placebo. The infusion will be given continuously for 7 days (or until discharge, if that occurs before 7 daysREC name
London - South East Research Ethics Committee
REC reference
20/HRA/3414
Date of REC Opinion
19 Aug 2020
REC opinion
Further Information Favourable Opinion